Abstract:Gynecological malignant tumor is an important cause of morbidity and mortality among women worldwide. Despite the continuous development of clinical means such as vaccine prevention, early screening, surgery, radiotherapy and chemotherapy, great progress has been made in the treatment of gynecological malignant tumors. However, in the current medical environment, unknown mechanisms, low sensitivity to drug resistance, difficulties in early diagnosis and other factors limit the prevention and treatment of gynecological malignant tumors such as breast cancer, ovarian cancer, cervical cancer and so on. Therefore, it is of great significance to clarify the pathogenesis and drug resistance mechanism of gynecological malignant tumors and find effective intervention targets and biomarkers for the prevention and treatment of gynecological malignant tumors. Iron death was first discovered and named by Dixon in 2012. It is a new programmed cell death mode. In recent years, continuous studies have shown that the mechanism of iron death is closely related to the occurrence, development and treatment of gynecological tumors. Therefore, starting with the pathogenesis of iron death, this paper describes its current research progress in gynecological malignant tumors, hoping to provide reference for future research.